Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency

Recruiting N/A Interventional Study
AVP Deficiency Diabetes Insipidus
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 50
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
28 (estimated)
Sponsor
University Hospital, Basel, Switzerland · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Part 1 1. Adult healthy controls 2. No medication (including hormonal contraception) 3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months Part 2 1. Confirmed diagnosis of AVP-Deficiency 2. Age ≥ 18 years 3. Female patients (…
Contacts

Andi Nikaj, MD

+41 61 328 57 43

andi.nikaj@usb.ch

CONTACT

Ursula Gobrecht-Keller, MD

+41 61 32 86028

ursula.gobrecht@usb.ch

CONTACT